These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 11847486)
1. Elevated levels of serum prolactin in patients with advanced multiple myeloma. Gadó K; Rimanóczi E; Hasitz A; Gigler G; Tóth BE; Nagy GM; Pálóczi K; Domján G Neuroimmunomodulation; 2001; 9(4):231-6. PubMed ID: 11847486 [TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of cyclo (His-Pro), an endogenous inhibitor of pituitary prolactin secretion, in systemic lupus erythematosus patients. Jara LJ; Prasad C; Espinoza LR Lupus; 1997; 6(3):258-60. PubMed ID: 9104733 [TBL] [Abstract][Full Text] [Related]
3. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients]. Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938 [TBL] [Abstract][Full Text] [Related]
4. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132 [TBL] [Abstract][Full Text] [Related]
5. Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients. Gadó K; Nagy G; Hasitz A; Tóth BE; Rimanóczi E; Domján G Neuroimmunomodulation; 2001; 9(2):95-102. PubMed ID: 11549891 [TBL] [Abstract][Full Text] [Related]
6. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI. D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952 [TBL] [Abstract][Full Text] [Related]
7. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma. Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099 [TBL] [Abstract][Full Text] [Related]
9. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma. Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032 [TBL] [Abstract][Full Text] [Related]
10. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma. Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043 [TBL] [Abstract][Full Text] [Related]
11. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease]. Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349 [TBL] [Abstract][Full Text] [Related]
12. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Jurisić V; Colović M Med Oncol; 2002; 19(3):133-9. PubMed ID: 12482123 [TBL] [Abstract][Full Text] [Related]